Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting

Cuisset, Thomas; Frère, Corinne; Quilici, Jacques; Gaborit, Bénédicte; Bali, Laurent; Poyet, Raphaël; Faille, Dorothée; Morange, Pierre‐Emmanuel; Alessi, Marie‐Christine; Bonnet, Jean‐Louis

doi:10.1016/j.ahj.2009.02.013

Cited by 75 publications

(43 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Variable effectiveness of antiplatelet drugs with regard to the complicated process of their action and many factors influencing their effect presents a complex problem for providing secondary prevention of IHD (Cuisset et al, 2009;Abaci and Kilickesmez, 2013).…”

Section: Discussionmentioning

confidence: 99%

“…The resulting platelet count for analysis was adjusted to 250 · 10 12 /L (range 221-282 · 10 12 /L). As a specific inducer for aspirin resistance assessment (Cuisset et al, 2009;Abaci and Kilickesmez, 2013), arachidonic acid at a concentration of 1 mM was used (Helena Biosciences). To determine an insufficient therapeutic effect with arachidonic acid-induced LTA (acetyl salicid acid induced aggregation (ASPI) test), the cut-off point was set at 25% (Slavik et al, 2011;Ú lehlová et al, 2011).…”

Section: Light Transmission Aggregometrymentioning

confidence: 99%

“…However, this therapy may fail in 5-30% of patients due to their resistance to antiplatelet drugs (Gurbel and Tandry, 2007;Cuisset et al, 2009). This phenomenon was first described in administration of ASA and subsequently in thienopyridines.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Genetic Polymorphisms of Platelet Receptors in Patients with Acute Myocardial Infarction and Resistance to Antiplatelet Therapy

Úlehlová

Slavík

Kučerová

et al. 2014

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Light Transmission Aggregometrymentioning

confidence: 99%

See 1 more Smart Citation

Genetic Polymorphisms of Platelet Receptors in Patients with Acute Myocardial Infarction and Resistance to Antiplatelet Therapy

Úlehlová

Slavík

Kučerová

et al. 2014

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

“…A limitation of this open-label part of the study is that we do not know the aspirin status before randomization (chronic treatment and dose) and how compliance to the recommended randomized dose was followed by the patients, compliance to aspirin therapy being a major issue for its efficacy. 47,48 Compared with low-dose aspirin, aspirin doses of 300 to 325 mg did not result in any significant differences in the primary outcome and in major bleeding (whatever the definition). The some- what surprising good safety of high-dose aspirin may be related to the short-term use of these higher doses compared with previous studies that reported safety concerns with high doses.…”

Section: What Impact Does Of the Current-oasis 7 Trial Have On The Asmentioning

confidence: 87%

Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7

Silvain

Bellemain-Appaix

Barthélémy

et al. 2011

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

“…So far there is no single cause of aspirin resistance. Recently, noncompliance was identified as the major cause of aspirin resistance in patients undergoing PCI [Cuisset et al 2009]. To overcome aspirin resistance higher dosages up to 325 mg have been suggested.…”

Section: Resistance To Aspirinmentioning

confidence: 99%

Clinical pharmacology of antithrombotic drugs in coronary artery disease

Fauler

2009

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Coronary heart disease is the leading cause of death in the Western world. Antithrombotic therapy is the cornerstone of its successful treatment. Clinical trials have demonstrated that antithrombotic therapy reduces the risk for recurrent myocardial infarction and cardiovascular death. Antiplatelet drugs and anticoagulants interfere with haemostasis and thus bleeding is a major risk factor of these drugs. The benefit of antithrombotic therapy must therefore be carefully balanced with the risk of bleeding and other potential adverse reactions of these drugs. However, to date there is no firm evidence that dosage adaptation of aspirin or clopidogrel according to platelet aggregation testing translates directly into any clinical benefit. Resistance to antithrombotic drugs is a serious problem because these patients are at a higher risk of myocardial infarction, stroke and cardiovascular death. It has most recently been demonstrated that resistance to clopidogrel is at least in part caused by polymorphism of CYP2C19. Clinical trials have also demonstrated that optimal benefit in different settings depends unequivocally on the meticulous choice of the various drugs. Thus, profound knowledge of the clinical pharmacological profiles of the different antithrombotic drugs is indispensable for successful treatment.

show abstract

Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting

Cited by 75 publications

References 15 publications

Genetic Polymorphisms of Platelet Receptors in Patients with Acute Myocardial Infarction and Resistance to Antiplatelet Therapy

Genetic Polymorphisms of Platelet Receptors in Patients with Acute Myocardial Infarction and Resistance to Antiplatelet Therapy

Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7

Clinical pharmacology of antithrombotic drugs in coronary artery disease

Contact Info

Product

Resources

About